Keensight Capital to acquire Inke from Neuraxpharm

• Neuraxpharm is a European pharmaceutical company based in Barcelona, Spain
• Keensight is a private equity manager dedicated to pan-European growth buyout investments
• The transaction is expected to be completed in May

Keensight Capital will acquire Inke, an inhalation active pharmaceutical ingredients (APIs) developer and manufacturer, from Neuraxpharm Group. No financial details of the transaction were disclosed.

Inke is based in Barcelona, Spain.

Neuraxpharm’s decision to divest Inke will allow it to solidify its market position in Europe and continues to expand its global footprint, according to a release.

Keensight’s investment will support Inke in expanding its footprint, broaden its offering, and grow its product portfolio, the release added.

“Inke’s positioning as a specialist in micronised APIs perfectly fits our strategy of investing in highly profitable, fast-growing leaders in niche segments,” said Amit Karna, partner at Keensight Capital.

The transaction is expected to be completed in May.

Neuraxpharm is a European pharmaceutical company focused on the treatment of central nervous system (CNS) disorders. The company is based in Barcelona, Spain.

Keensight is a private equity manager dedicated to pan-European growth buyout investments. The firm is based in Paris, France.

Keensight was advised by Rothschild & Co (M&A), Garrigues and Paul Hastings (legal), Bain & Company (commercial and strategic) and Alvarez & Marsal (financial).